Business Description
Nextbiomedical Co Ltd
ISIN : KR7389650003
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.24 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -1.95 | |||||
Debt-to-EBITDA | -1.78 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.58 | |||||
Beneish M-Score | -2.82 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.8 | |||||
3-Year EBITDA Growth Rate | 41.8 | |||||
3-Year EPS without NRI Growth Rate | 7.5 | |||||
3-Year FCF Growth Rate | 10.7 | |||||
3-Year Book Growth Rate | 53.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.93 | |||||
9-Day RSI | 37.25 | |||||
14-Day RSI | 45.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.53 | |||||
Quick Ratio | 0.47 | |||||
Cash Ratio | 0.42 | |||||
Days Inventory | 270.38 | |||||
Days Sales Outstanding | 46.09 | |||||
Days Payable | 6.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -0.15 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.19 | |||||
Operating Margin % | -107.05 | |||||
Net Margin % | -154.06 | |||||
FCF Margin % | -86.53 | |||||
ROA % | -24.35 | |||||
ROIC % | -11.63 | |||||
3-Year ROIIC % | 1.96 | |||||
ROC (Joel Greenblatt) % | -59.98 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 46.55 | |||||
EV-to-EBIT | -41.4 | |||||
EV-to-EBITDA | -44.39 | |||||
EV-to-Revenue | 58.92 | |||||
EV-to-FCF | -73.49 | |||||
Earnings Yield (Greenblatt) % | -2.41 | |||||
FCF Yield % | -1.45 |